Ionis Pharmaceuticals Shares Sink After Late-Stage Trial Failed to Meet Primary Goal
By Connor Hart
Shares of Ionis Pharmaceuticals tumbled after the company said a late-stage trial of its drug for a rare type of heart disease failed to meet its primary efficacy endpoint.
The stock sank 23%, to $65.10, in premarket trading Thursday. Through Wednesday's close, shares are up 6% year to date.
Ionis said the treatment, eplontersen, didn't provide a statistically-significant benefit to patients with transthyretin-mediated amyloid cardiomyopathy.
Transthyretin-mediated amyloid cardiomyopathy is an underdiagnosed and potentially fatal disease of the heart muscle in which a protein called transthyretin builds up in the heart, nerves and other organs.
"Although we are disappointed that the study did not meet the primary endpoint, these results have the potential to guide the treatment landscape for ATTR-CM and contribute to advancing future care for patients," Ionis Chief Executive Brett Monia said.
The company noted the drug, which was developed in partnership with AstraZeneca, was well tolerated, with a favorable safety profile consistent with previous results.
Shares of the U.K. drugmaker were also off ahead of Thursday's opening bell, down 8.2% to $173.85.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
July 09, 2026 08:19 ET (12:19 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States